|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Reserpine#Use in Specific Populations]] |
| {{Reserpine}}
| |
| {{CMG}}; {{AE}} {{AK}}
| |
| | |
| ==Use In Specific Populations==
| |
| ===Pregnancy Category C===
| |
| | |
| Reserpine administered parenterally has been shown to be teratogenic in rats at doses up to 2 mg/kg and to have an embryocidal effect in guinea pigs given dosages of 0.5 mg daily.
| |
| | |
| There are no adequate and well-controlled studies of reserpine in pregnant women. Reserpine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
| |
| | |
| ====Nonteratogenic Effects====
| |
| | |
| Reserpine crosses the placental barrier, and increased respiratory tract secretions, [[nasal congestion]], [[cyanosis]], and [[anorexia ]]may occur in [[neonates ]]of reserpine-treated mothers.
| |
| | |
| ===Nursing Mothers===
| |
| | |
| Reserpine is excreted in maternal breast milk, and increased respiratory tract secretions, nasal congestion, [[cyanosis]], and [[anorexia ]]may occur in breast-fed infants. Because of the potential for adverse reactions in nursing infants and the potential for tumorigenicity shown for reserpine in animal studies, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. | |
| | |
| ===Pediatric Use===
| |
| | |
| Safety and effectiveness in children have not been established by means of controlled clinical trials, although there is experience with the use of reserpine in children (see [[Reserpine dosage and administration|DOSAGE AND ADMINISTRATION]].) Because of adverse effects such as emotional depression and lability, sedation, and stuffy nose, reserpine is not usually recommended as a step-2 drug in the treatment of hypertension in children.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = RESERPINE TABLET [EON LABS, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3a4d74d7-2e63-4789-b50e-af17ced92462 | publisher = | date = | accessdate = 7 March 2014 }}</ref>
| |
| | |
| | |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |